Chemotherapy of small cell lung cancer

Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer

“…The extent of dose intensification in our study is compa rable to results from other trials and tumor types [19,[34][35][36][37][38][39]. WHO grade 4 neutropenia or thrombocytopenia occurred in about 60% of our patients with an overall median duration of 4 days (range 1-17) and 2 days (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Like others, we have found no evidence of cumulative neutropenia across different intervals.…”

“…SCLC is characterized by rapid cellular proliferation, short tumor doubling times, early dissemination, and high chemo-and radiosensitivity. Sys temic chemotherapy is therefore the first-line treatment in patients with this tumor type [1], High single agent activity has been shown for carboplatin, ifosfamide, and ctoposide with response rates of 40-60% [2][3][4][5][6]. Although overall response rates were further increased with combi nation therapy, long-term survival has not been signifi cantly improved [7][8][9][10][11][12].…”

Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer

“…The extent of dose intensification in our study is compa rable to results from other trials and tumor types [19,[34][35][36][37][38][39]. WHO grade 4 neutropenia or thrombocytopenia occurred in about 60% of our patients with an overall median duration of 4 days (range 1-17) and 2 days (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Like others, we have found no evidence of cumulative neutropenia across different intervals.…”

“…SCLC is characterized by rapid cellular proliferation, short tumor doubling times, early dissemination, and high chemo-and radiosensitivity. Sys temic chemotherapy is therefore the first-line treatment in patients with this tumor type [1], High single agent activity has been shown for carboplatin, ifosfamide, and ctoposide with response rates of 40-60% [2][3][4][5][6]. Although overall response rates were further increased with combi nation therapy, long-term survival has not been signifi cantly improved [7][8][9][10][11][12].…”

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

“…However, no detectable increase in the risk of toxic death was disclosed. It is widely accepted that prognosis of SCLC is improved by chemotherapy (Hansen et al, 1991). Combination chemotherapy was the main treatment in the 1970s.…”

“…Chemotherapy is the main treatment for small-cell lung cancer (SCLC), one of the solid tumours which responds best to cytotoxic agents, and survival benefit has been widely demonstrated (Hansen et al, 1991). Various drug combinations have been used in sequential chemotherapies in order to improve both response rate and survival.…”

Die Bedeutung von CYFRA 21-1 in der pneumologischen Differentialdiagnostik - Vergleichende Untersuchung mittels Enzymimmunoassay und Radioimmunoassay

“…Die unterschiedliche Histologie der Bronchialkarzinomef ührt jedoch zu weitreichenden Konsequenzen in therapeutischer Vorgehensweise und Prognose. Das kleinzellige Bronchialkarzinom weist aufgrund seiner raschen Metastasierung eine schlechte Prognose auf und wird bei gleichzeitig hoher Chemosensitivität üblicherweise chemotherapeutisch behandelt (9,11). Dagegen werden die nichtkleinzelligen Bronchialkarzinome einer chirurgischen Therapie zugeführt und weisen eine bessere Prognose auf (14).…”

Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer

“…The extent of dose intensification in our study is compa rable to results from other trials and tumor types [19,[34][35][36][37][38][39]. WHO grade 4 neutropenia or thrombocytopenia occurred in about 60% of our patients with an overall median duration of 4 days (range 1-17) and 2 days (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Like others, we have found no evidence of cumulative neutropenia across different intervals.…”

“…SCLC is characterized by rapid cellular proliferation, short tumor doubling times, early dissemination, and high chemo-and radiosensitivity. Sys temic chemotherapy is therefore the first-line treatment in patients with this tumor type [1], High single agent activity has been shown for carboplatin, ifosfamide, and ctoposide with response rates of 40-60% [2][3][4][5][6]. Although overall response rates were further increased with combi nation therapy, long-term survival has not been signifi cantly improved [7][8][9][10][11][12].…”

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

“…However, no detectable increase in the risk of toxic death was disclosed. It is widely accepted that prognosis of SCLC is improved by chemotherapy (Hansen et al, 1991). Combination chemotherapy was the main treatment in the 1970s.…”

“…Chemotherapy is the main treatment for small-cell lung cancer (SCLC), one of the solid tumours which responds best to cytotoxic agents, and survival benefit has been widely demonstrated (Hansen et al, 1991). Various drug combinations have been used in sequential chemotherapies in order to improve both response rate and survival.…”

Die Bedeutung von CYFRA 21-1 in der pneumologischen Differentialdiagnostik - Vergleichende Untersuchung mittels Enzymimmunoassay und Radioimmunoassay

“…Die unterschiedliche Histologie der Bronchialkarzinomef ührt jedoch zu weitreichenden Konsequenzen in therapeutischer Vorgehensweise und Prognose. Das kleinzellige Bronchialkarzinom weist aufgrund seiner raschen Metastasierung eine schlechte Prognose auf und wird bei gleichzeitig hoher Chemosensitivität üblicherweise chemotherapeutisch behandelt (9,11). Dagegen werden die nichtkleinzelligen Bronchialkarzinome einer chirurgischen Therapie zugeführt und weisen eine bessere Prognose auf (14).…”

Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer

“…The extent of dose intensification in our study is compa rable to results from other trials and tumor types [19,[34][35][36][37][38][39]. WHO grade 4 neutropenia or thrombocytopenia occurred in about 60% of our patients with an overall median duration of 4 days (range 1-17) and 2 days (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Like others, we have found no evidence of cumulative neutropenia across different intervals.…”

“…SCLC is characterized by rapid cellular proliferation, short tumor doubling times, early dissemination, and high chemo-and radiosensitivity. Sys temic chemotherapy is therefore the first-line treatment in patients with this tumor type [1], High single agent activity has been shown for carboplatin, ifosfamide, and ctoposide with response rates of 40-60% [2][3][4][5][6]. Although overall response rates were further increased with combi nation therapy, long-term survival has not been signifi cantly improved [7][8][9][10][11][12].…”

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

“…However, no detectable increase in the risk of toxic death was disclosed. It is widely accepted that prognosis of SCLC is improved by chemotherapy (Hansen et al, 1991). Combination chemotherapy was the main treatment in the 1970s.…”

“…Chemotherapy is the main treatment for small-cell lung cancer (SCLC), one of the solid tumours which responds best to cytotoxic agents, and survival benefit has been widely demonstrated (Hansen et al, 1991). Various drug combinations have been used in sequential chemotherapies in order to improve both response rate and survival.…”

Die Bedeutung von CYFRA 21-1 in der pneumologischen Differentialdiagnostik - Vergleichende Untersuchung mittels Enzymimmunoassay und Radioimmunoassay

“…Die unterschiedliche Histologie der Bronchialkarzinomef ührt jedoch zu weitreichenden Konsequenzen in therapeutischer Vorgehensweise und Prognose. Das kleinzellige Bronchialkarzinom weist aufgrund seiner raschen Metastasierung eine schlechte Prognose auf und wird bei gleichzeitig hoher Chemosensitivität üblicherweise chemotherapeutisch behandelt (9,11). Dagegen werden die nichtkleinzelligen Bronchialkarzinome einer chirurgischen Therapie zugeführt und weisen eine bessere Prognose auf (14).…”